000282550 001__ 282550
000282550 005__ 20251218103441.0
000282550 0247_ $$2doi$$a10.1007/s00406-025-02013-z
000282550 0247_ $$2pmid$$apmid:40314736
000282550 0247_ $$2pmc$$apmc:PMC12638345
000282550 0247_ $$2ISSN$$a1433-8491
000282550 0247_ $$2ISSN$$a0003-9373
000282550 037__ $$aDZNE-2025-01313
000282550 041__ $$aEnglish
000282550 082__ $$a610
000282550 1001_ $$0P:(DE-2719)9000176$$aKurz, Carolin$$b0
000282550 245__ $$aPlasma biomarkers of amyloid, tau & neuroinflammation in Alzheimer's disease and corticobasal syndrome.
000282550 260__ $$aHeidelberg$$bSpringer$$c2025
000282550 3367_ $$2DRIVER$$aarticle
000282550 3367_ $$2DataCite$$aOutput Types/Journal article
000282550 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1764679643_28227
000282550 3367_ $$2BibTeX$$aARTICLE
000282550 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282550 3367_ $$00$$2EndNote$$aJournal Article
000282550 520__ $$aBlood-based biomarkers (BBBMs) could significantly facilitate the diagnosis of Alzheimer's disease (AD) and non-AD dementia by providing less invasive alternatives to cerebrospinal fluid (CSF) and positron emission tomography (PET) imaging.This study investigated how well the BBBMs-amyloid-β (Aβ) 1-42/1-40 ratio, phosphorylated tau181 (pTau181), apolipoprotein E4 (ApoE4), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL)-reflect thorough clinical work-up validated by PET and CSF biomarkers in participants with AD (n = 27), Aβ-negative CBS (n = 26), and agematched healthy controls (HC) (n = 17).Factor and correlation explored biomarker associations. Bayesian regression, backward selection regression, and ROC curve analysis were applied to identify optimal biomarker combinations and diagnostic cut-offs.In AD cases, pTau181 and ApoE4 levels were elevated, and the Aβ1-42/1-40 ratio was reduced. ROC analysis showed high accuracy for pTau181, ApoE4 and Aβ1-42/1-40 in discriminating AD from HC, with a combination significantly improving performance. However, limited fold change, and high variability reduced the diagnostic applicability of Aβ1-42/1-40 ratio. Elevated NfL levels were the most reliable biomarker for CBS-Aβ(-) cases. GFAP showed limited discriminatory power due to overlapping levels, suggesting that it may not serve as a disease-specific biomarker but may be indicative of general neurodegeneration.This study highlights the diagnostic utility of pTau181, ApoE4 and the Aβ1-42/1-40 ratio for AD and NfL in the CBS-Aβ(-) cases and emphasizes the added value of combined biomarker models for group differentiation. Prospective studies will help validate these findings and refine clinical thresholds.
000282550 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000282550 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x1
000282550 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000282550 650_7 $$2Other$$aApolipoprotein E (ApoE4)
000282550 650_7 $$2Other$$aBeta-amyloid 1-40 (Aβ1-40)
000282550 650_7 $$2Other$$aBeta-amyloid 1-42 (Aβ1-42)
000282550 650_7 $$2Other$$aGlial fibrillary acidic protein (GFAP)
000282550 650_7 $$2Other$$aNeurofilament light chain (NfL)
000282550 650_7 $$2Other$$aNon-Alzheimer's disease dementia; beta
000282550 650_7 $$2Other$$aPhosphorylated tau (pTau)
000282550 650_7 $$2NLM Chemicals$$atau Proteins
000282550 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000282550 650_7 $$2NLM Chemicals$$aBiomarkers
000282550 650_7 $$2NLM Chemicals$$aPeptide Fragments
000282550 650_7 $$2NLM Chemicals$$aGlial Fibrillary Acidic Protein
000282550 650_7 $$2NLM Chemicals$$aNeurofilament Proteins
000282550 650_7 $$2NLM Chemicals$$aApolipoprotein E4
000282550 650_7 $$2NLM Chemicals$$aamyloid beta-protein (1-42)
000282550 650_7 $$2NLM Chemicals$$aneurofilament protein L
000282550 650_7 $$2NLM Chemicals$$aGFAP protein, human
000282550 650_7 $$2NLM Chemicals$$aamyloid beta-protein (1-40)
000282550 650_7 $$2NLM Chemicals$$aMAPT protein, human
000282550 650_2 $$2MeSH$$aHumans
000282550 650_2 $$2MeSH$$aAlzheimer Disease: blood
000282550 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000282550 650_2 $$2MeSH$$atau Proteins: blood
000282550 650_2 $$2MeSH$$aFemale
000282550 650_2 $$2MeSH$$aAmyloid beta-Peptides: blood
000282550 650_2 $$2MeSH$$aBiomarkers: blood
000282550 650_2 $$2MeSH$$aAged
000282550 650_2 $$2MeSH$$aMale
000282550 650_2 $$2MeSH$$aPeptide Fragments: blood
000282550 650_2 $$2MeSH$$aGlial Fibrillary Acidic Protein: blood
000282550 650_2 $$2MeSH$$aMiddle Aged
000282550 650_2 $$2MeSH$$aNeurofilament Proteins: blood
000282550 650_2 $$2MeSH$$aNeuroinflammatory Diseases: blood
000282550 650_2 $$2MeSH$$aApolipoprotein E4: blood
000282550 650_2 $$2MeSH$$aAged, 80 and over
000282550 650_2 $$2MeSH$$aCorticobasal Degeneration: blood
000282550 650_2 $$2MeSH$$aCorticobasal Degeneration: diagnosis
000282550 650_2 $$2MeSH$$aPositron-Emission Tomography
000282550 7001_ $$aCarli, Laura$$b1
000282550 7001_ $$0P:(DE-2719)9001027$$aGuersel, Selim$$b2$$udzne
000282550 7001_ $$aSchrurs, Isabelle$$b3
000282550 7001_ $$aJethwa, Alexander$$b4
000282550 7001_ $$aCarboni, Margherita$$b5
000282550 7001_ $$aBittner, Tobias$$b6
000282550 7001_ $$aHortsch, Sayuri$$b7
000282550 7001_ $$aKeeser, Daniel$$b8
000282550 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b9$$udzne
000282550 7001_ $$aBurow, Lena$$b10
000282550 7001_ $$aHaeckert, Jan$$b11
000282550 7001_ $$aKoriath, Carolin A M$$b12
000282550 7001_ $$0P:(DE-2719)9003524$$aTatò, Maia Lucia$$b13$$udzne
000282550 7001_ $$aUtecht, Julia$$b14
000282550 7001_ $$aPapazov, Boris$$b15
000282550 7001_ $$0P:(DE-2719)2812759$$aMorenas Rodriguez, Estrella$$b16
000282550 7001_ $$aPogarell, Oliver$$b17
000282550 7001_ $$0P:(DE-2719)9000852$$aPalleis, Carla$$b18$$udzne
000282550 7001_ $$0P:(DE-2719)9000882$$aWeidinger, Endy$$b19$$udzne
000282550 7001_ $$0P:(DE-2719)9003671$$aStöcklein, Sophia$$b20$$udzne
000282550 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b21$$udzne
000282550 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter$$b22$$udzne
000282550 7001_ $$0P:(DE-2719)9001808$$aRauchmann, Boris-Stephan$$b23$$udzne
000282550 7001_ $$0P:(DE-2719)2812234$$aPerneczky, Robert$$b24$$eLast author$$udzne
000282550 773__ $$0PERI:(DE-600)2793981-9$$a10.1007/s00406-025-02013-z$$gVol. 275, no. 8, p. 2255 - 2273$$n8$$p2255 - 2273$$tArchiv für Psychiatrie und Nervenkrankheiten$$v275$$x1433-8491$$y2025
000282550 8564_ $$uhttps://pub.dzne.de/record/282550/files/DZNE-2025-01313.pdf$$yOpenAccess
000282550 8564_ $$uhttps://pub.dzne.de/record/282550/files/DZNE-2025-01313.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000282550 909CO $$ooai:pub.dzne.de:282550$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000282550 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001027$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000282550 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001539$$aExternal Institute$$b9$$kExtern
000282550 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9003524$$aExternal Institute$$b13$$kExtern
000282550 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812759$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b16$$kDZNE
000282550 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000852$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b18$$kDZNE
000282550 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000882$$aExternal Institute$$b19$$kExtern
000282550 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9003671$$aExternal Institute$$b20$$kExtern
000282550 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b21$$kDZNE
000282550 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b22$$kDZNE
000282550 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001808$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b23$$kDZNE
000282550 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812234$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b24$$kDZNE
000282550 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000282550 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x1
000282550 9141_ $$y2025
000282550 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-05
000282550 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-05
000282550 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000282550 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000282550 9201_ $$0I:(DE-2719)5000022$$kAG Dichgans$$lVascular Cognitive Impairment & Post-Stroke Dementia$$x0
000282550 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x1
000282550 9201_ $$0I:(DE-2719)1110008$$kAG Simons$$lMolecular Neurobiology$$x2
000282550 9201_ $$0I:(DE-2719)1111016$$kAG Levin$$lClinical Neurodegeneration$$x3
000282550 980__ $$ajournal
000282550 980__ $$aVDB
000282550 980__ $$aUNRESTRICTED
000282550 980__ $$aI:(DE-2719)5000022
000282550 980__ $$aI:(DE-2719)1111015
000282550 980__ $$aI:(DE-2719)1110008
000282550 980__ $$aI:(DE-2719)1111016
000282550 9801_ $$aFullTexts